U.S., May 1 -- ClinicalTrials.gov registry received information related to the study (NCT06952452) titled 'Pharmacogenomics of antiVEGF in Patients With Age-Associated Macular Degeneration (AMD)' on Oct. 28, 2024.
Brief Summary: This is a phase III, multicenter, randomized double-blinded clinical trial with two parallel groups (ranibizumab and bevacizumab) and an observational follow-up of patients who meet elegibility criteria and decline participation due to treatment randomization. It will be performed involving 630 eyes from patients with wet age-related macular degeneration (wAMD) diagnosis without another eye disease. This clinical trial compares the treatment response for 3 years, considering genetic variants already studied between...